Biotech Catalysts to Watch: Key Developments for August 2026

In August 2026, several pivotal biotech catalysts could sway investor sentiment and market trends. We're tracking seven significant events, each with its own key dates and approval probabilities (PoA). Notably, CAPR's Deramiocel leads with a 77% PoA, while SLRX's pan-coronavirus antiviral program lags at just 5%.

The full biotech catalysts to watch

CAPR's Deramiocel: A Pivotal Decision on August 22, 2026

Deramiocel (CAP-1002) from Capricor Therapeutics targets Duchenne muscular dystrophy (DMD) and holds a strong 77% chance of FDA approval. The decision is due on August 22, 2026, after a successful Phase 3 HOPE-3 trial with 106 boys, which hit its primary and all secondary endpoints. The trial was rigorous, using a randomized, double-blind, placebo-controlled design, focusing on upper limb function with the Performance of the Upper Limb test (PUL 2.0). With DMD's current treatments mainly addressing skeletal or cardiac issues, Deramiocel's dual mechanism could offer significant benefits. However, past regulatory hurdles, including a Complete Response Letter from the FDA, raise questions about the company's ability to meet regulatory demands. The DMD therapeutic market shows a large unmet need, which favors Deramiocel, though regulatory approval remains uncertain.

TLSA's Foralumab: Promising Data Amidst High Risks

Tiziana Life Sciences' Foralumab, an intranasal anti-CD3 monoclonal antibody, is in a Phase 2a trial for non-active secondary progressive multiple sclerosis (na-SPMS). Top-line data is expected in October 2026, with a 20% approval probability. Preliminary data from 10 patients showed stabilized Expanded Disability Status Scale (EDSS) scores and reduced fatigue, but the small sample and lack of pivotal efficacy results temper expectations. Na-SPMS's progression independent of relapse complicates the approval path. The absence of Fast Track or Breakthrough Therapy designations and prior Phase 3 data adds to the uncertainty. Investors should watch enrollment and data updates closely, as these will be critical for Foralumab's future.

MPLT's ML-007C-MA: Navigating the Schizophrenia Landscape

MapLight Therapeutics' ML-007C-MA is in Phase 2 trials for schizophrenia, with results due by August 31, 2026. Its approval probability is 23%, reflecting cautious optimism amid uncertainties. This drug combines an M1/M4 muscarinic agonist with a peripherally acting anticholinergic to reduce central cholinergic side effects. Despite schizophrenia's high prevalence, treatment options face challenges in efficacy and tolerability. The recent approval of COBENFY, another M1/M4 agonist, sets a benchmark, but ML-007C-MA needs to show equal or better efficacy. No regulatory designations could affect its approval path. Upcoming results and a potential Phase 3 trial initiation make this a crucial period for both the drug and MapLight Therapeutics.

SLRX's Pan-Coronavirus Antiviral: A Long Road Ahead

Salarius Pharmaceuticals' pan-coronavirus antiviral program, now part of Decoy Therapeutics, remains in the preclinical phase, with an IND application expected by November 2026. The approval probability is a low 5%, typical for early-stage antivirals. There's a lack of clinical trial data and established safety or efficacy profiles, raising concerns. Historically, pre-IND antiviral candidates face significant challenges, especially in meeting regulatory standards. Without accelerated designations, the path to approval is fraught with uncertainty. Investors should keep an eye on IND filing timelines and preclinical results to gauge the program's potential.

Gated Items: A Broader Look at Upcoming Catalysts

Beyond the highlighted catalysts, several other gated items present opportunities and risks in biotech. INO's INO-3107, with a high approval probability, awaits a decision on October 30, 2026, attracting strong investor interest. Conversely, ZNTL's azenosertib for platinum-resistant ovarian cancer has a low PoA despite targeting a critical indication. TENX's TNX-103 also faces an August 29, 2026, decision with a low PoA. Already discussed are CAPR's Deramiocel and MPLT's ML-007C-MA. The varied PoA across these candidates highlights the biotech sector's complexity as we enter late 2026. Investors should stay vigilant, analyzing data and regulatory paths to navigate this dynamic market.

The bottom line

August 2026 presents a dynamic biotech landscape with critical catalysts ahead. Staying informed on these developments is essential for investors aiming to seize potential opportunities.